IR-MED Inc. announced the appointment of Lynn Eschenbacher PharmD, MBA, FASHP, CPEL to its Advisory Board. Dr. Eschenbacher is an innovative business development executive with extensive experience in the healthcare industry. As CEO and Founder of Echelon Health Strategies, she develops and delivers innovative strategies, operational excellence, and relationship networking to drive growth resulting in positive business outcomes and profitability.

Focused on addressing access, adherence, and affordability across the continuum of healthcare, Dr. Eschenbacher works to ensure equity. She addresses impactful issues by engaging with Boards of Pharmacy, professional organizations, and the U.S. Congress. Dr. Eschenbacher serves as Venture Partner at SpringTide, a healthcare focused venture capital firm, Chief Customer Officer at RxLive, Strategic Advisory Board Member at Atlas Health, as well as several other key roles with innovative healthcare companies.

Among Dr. Eschenbacher's many accomplishments, she held the position of the Chief Pharmacy Officer and Vice President Medication Management at Ascension Healthcare. Dr. Eschenbacher also held a number of positions including Medication Safety Officer at Duke University Health System. She earned her doctor of pharmacy from The University of Texas at Austin, an MBA from Duke University, and a BS in Biology from Indiana University.

As an Advisory Board member at IR-MED, Dr. Eschenbacher will advise on the development and strategic market launch of the Company's lead product, PressureSafe, which uses penetrating infrared light to ‘look' beneath the skin's surface, senses biomarkers and structural changes in tissue layers for the early detection of pressure injuries. The Company plans to file for regulatory approval of PressureSafe with the U.S. Food and Drug Administration in fourth quarter of 2023, with commercial launch soon to follow, pending approval.